echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: SLC38A4 regulates Wnt/β-catenin/MYC/HMGCS2 signaling pathway to inhibit the occurrence and development of hepatocellular carcinoma

    Br J Cancer: SLC38A4 regulates Wnt/β-catenin/MYC/HMGCS2 signaling pathway to inhibit the occurrence and development of hepatocellular carcinoma

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths worldwide


    Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths worldwide


    More and more evidences show that HCC and embryonic liver development share many common molecular characteristics




    In this study, the researchers studied the expression levels and clinical relevance of SLC38A4 and HMGCS2 through qRT-PCR, Western blot, TCGA and GEO data sets, and studied the biological effects of SLC38A4 through functional assays




    Compared with adults, the expression of Slc38a4 in fetal liver is down-regulated

    Compared with adults, the expression of Slc38a4 in fetal liver is down-regulated

    Functional studies have shown that knocking out SLC38A4 can promote the proliferation, stem cell characteristics and migration ability of HCC cells, inhibit the apoptosis of HCC cells in vitro, and further inhibit the occurrence of HCC tumors in vivo


    stem cell



    The expression of SLC38A4 is down-regulated in HCC tissues and is negatively correlated with the prognosis of patients

    The expression of SLC38A4 is down-regulated in HCC tissues and is negatively correlated with the prognosis of patients

    All in all, the results of the study showed that down-regulation of SLC38A4 expression is considered a new carcinoembryonic event, and SLC38A4 has also been identified as a new tumor suppressor in the development of HCC


    The down-regulation of SLC38A4 expression is considered to be a new carcinoembryonic event, and SLC38A4 has also been identified as a new tumor suppressor in the occurrence and development of HCC



    SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.